Follow us:

科研产品

  • 基因表达PCR芯片
  • 体细胞突变PCR芯片
  • 拷贝数变化PCR芯片
  • 基因分型PCR芯片
  • 蛋白表达抗体芯片
  • 蛋白磷酸化抗体芯片
  • 蛋白质相互作用芯片
  • 引物和探针
  • 常规分子生物学试剂

  • 临床产品

  • 个性化用药
  • 易感基因检测
  • 生物标志物试剂盒

  • > 产品目录 > 科研产品 > 体细胞突变PCR芯片 > 甲状腺癌体细胞突变PCR芯片
    人甲状腺癌体细胞突变PCR芯片适用于快速、准确的进行甲状腺癌相关基因突变的检测,包括:AKT1, BRAF, CDKN2A, CTNNB1/beta-catenin, GNAS, HRAS, KRAS, MET, NRAS, PIK3CA, RET和 TSHR。对上述基因突变的深入研究有助于科研工作者更好的了解肿瘤的发生机制,并为临床靶向用药提供可靠的分子机理。
    甲状腺癌体细胞突变PCR芯片
    人甲状腺癌体细胞突变PCR芯片适用于快速、准确的进行甲状腺癌相关基因突变的检测,包括:AKT1, BRAF, CDKN2A, CTNNB1/beta-catenin, GNAS, HRAS, KRAS, MET, NRAS, PIK3CA, RET和 TSHR。对上述基因突变的深入研究有助于科研工作者更好的了解肿瘤的发生机制,并为临床靶向用药提供可靠的分子机理。利用单个或多个体细胞突变信息检测关键信号通路异常已被广泛应用于临床研究。例如: EGFR和KRAS基因突变能够预测靶向该位点的药物治疗响应。人甲状腺癌体细胞突变PCR芯片覆盖广泛,适用于甲状腺癌以及含有此类突变的其他肿瘤的突变检测,并有望为临床相关疾病提供潜在药物治疗靶点。该芯片包含81个甲状腺癌中最常见的,具有重要功能和生理学意义的突变位点。突变位点主要由多种体细胞突变数据库以及经同行评阅的科学文献筛选得到,展示了超过8400例甲状腺癌患者的最常见突变。
     
    Assay functional annotations
    AKT1: 1 Assay
    The mutation assay detects the best known AKT1 mutation, c.49G>A, p.E17K. This is a PH domain mutation that results in constitutive targeting of AKT1 to plasma membrane.
    BRAF: 2 Assays
    There are two major classes of BRAF mutations. One class leads to increased BRAF kinase activity, such as the p. V600E mutation. The other class leads to impaired kinase activity, such as the p.G469A mutation.
    CDKN2A: 1 Assay
    The top CDKN2A loss-of-function mutations occur in the consensus ankyrin domain, which leads to inability to form stable complexes with its targets.
    CTNNB1: 5 Assays
    The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta.
    EGFR: 3 Assays
    The most frequently identified EGFR mutations include P-loop and activation loop point mutations, kinase domain deletions, and insertion mutations.
    GNAS: 3 Assays
    Mutations in this gene result in pseudohypoparathyroidism type 1a (PHP1a), which has an atypical autosomal dominant inheritance pattern requiring maternal transmission for full penetrance.
    HRAS: 9 Assays
    The mutation assays include the most important HRAS mutations identified in cancers at codons 12, 13, and 61.
    KRAS: 11 Assays
    The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
    MET: 1 Assay
    These assays detect the most frequently identified c-MET gain-of-function mutations, such as tyrosine kinase domain and juxtamembrane domain point mutations.
    NRAS: 8 Assays
    The mutation assays include the most important NRAS mutations at codons 12, 13, and 61.
    PIK3CA: 14 Assays
    The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors.
    RET: 8 Assays
    The mutations p.E768D, p.A883F, and p.M918T lie in the protein kinase domain and soluble RET kinase fragment. Most of the remaining mutations lie in predicted extracellular domains.
    TSHR: 15 Assays
    The represented mutations lie in the transmembrane region of this protein and often induce a gain-of-function by increasing basal cAMP levels but could also make the protein slightly less responsive to TSH stimulation. Other mutations lie in either cytoplasmic or extracellular domains of the protein.
    规格:81个位点/array    1sample/array 



    更多了解产品和解决方案>>
    美好杏园你我共创